Skip to content

Travere Therapeutics, Inc. TVTX Operating Lease Liabilities

Operating Lease Liabilities at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.99B+29.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$14.22M+189%
Arrowhead Research logo
Arrowhead ResearchARWR
$100.11M-6.9%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$90.07M+22.4%
Scholar Rock logo
Scholar RockSRRK
$2.98M-62.3%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$7.44M-24.1%

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.13B+72.3%
Enterprise value$5.07B+65.5%
P/S9.6×-1.3×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s operating lease liabilities?
Travere Therapeutics, Inc. (TVTX) reported operating lease liabilities of $9.57M in Q1 2026.
How has Travere Therapeutics, Inc.'s operating lease liabilities changed year-over-year?
Travere Therapeutics, Inc.'s operating lease liabilities decreased by 38.6% year-over-year, from $15.58M to $9.57M.
What is the long-term trend for Travere Therapeutics, Inc.'s operating lease liabilities?
Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s operating lease liabilities has grown at a -17.0% compound annual growth rate (CAGR), from $28.34M to $11.13M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.